← Leaderboards
Rodolfo Galindo
University Of Miami School Of Medicine
$1,163,897
Attributed
$1,163,897
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $295.1K · FY2020–25$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,163,897 · 2
By mechanism
K23$933,647 · 1
R03$230,250 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Miami School Of Medicine
Same institution · by research overlap
- Cherie L Stabler$9,274,604
- Tatjana Rundek$11,942,766
- Jose G Romano$8,270,001
- Chris Michael Li$161,206
- Naresh Punjabi$19,979,932
Others in their field
Other Emerging Leaders on “Monitor”
- Bambra Strokes · Ppd Development Lp$461,655,950
- Kimberly Smith · Ppd Development Lp$116,656,661
- Yunda Huang · Fred Hutchinson Cancer Center$71,488,059
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Martha Hering · Westat, Inc.$57,098,843
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
MonitorPatient OrientedHigh RiskInsulin SensitivityMortalityNon-Insulin-Dependent Diabetes MellitusGlucoseGlycemic ControlHyperglycemiaInsulinDiabetes MellitusDialysis ProcedureDiabetes ManagementMultidisciplinaryEmergency Department VisitEnd Stage Renal FailureGlucose MetabolismBlood CapillariesAffectHospitalizationClinical ResearchHypoglycemiaDatabasesPattern
Grant awards (8)
Pharmaco-epidemiology of diabetes in patients with end-stage kidney disease$115,125
R03 · FY2025 · DK · contact PI
Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease(ESRD) Patients with Type 2 Diabetes$180,005
K23 · FY2024 · DK · contact PI
Pharmaco-epidemiology of diabetes in patients with end-stage kidney disease$115,125
R03 · FY2024 · DK · contact PI
Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease(ESRD) Patients with Type 2 Diabetes$181,440
K23 · FY2023 · DK · contact PI
Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease (ESRD) Patients with Type 2 Diabetes$1
K23 · FY2023 · DK · contact PI
Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease (ESRD) Patients with Type 2 Diabetes$189,395
K23 · FY2022 · DK · contact PI
Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease (ESRD) Patients with Type 2 Diabetes$191,069
K23 · FY2021 · DK · contact PI
Use of Continuous Glucose Monitoring (CGM) in End-Stage Renal Disease (ESRD) Patients with Type 2 Diabetes$191,737
K23 · FY2020 · DK · contact PI